Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oleocanthal is a naturally occurring phenolic compound, specifically a phenylethanoid and a monophenolic secoiridoid, found exclusively in extra virgin olive oil[1][2][3][4][9]. Its chemical structure is 2-(p-hydroxyphenyl)ethyl ester of (3S)-4-formyl-3-(2-oxoethyl)hex-4-enoic acid, and it is a tyrosol ester related to oleuropein[8][9]. Oleocanthal is responsible for the characteristic pungency (“throat burn”) in high-quality olive oils[4][5][7]. The principal mechanism of action is its non-selective inhibition of cyclooxygenase-1 and cyclooxygenase-2 (COX-1, COX-2), similar to ibuprofen but with greater potency on a molar basis[1][3][5][7][9]. It also disrupts multiple signaling pathways in cancer and inflammatory processes, including inhibition of mTOR, STAT3, Akt, MAPK, and B-Raf, and suppresses the inflammasome cascade[1]. Oleocanthal has shown anti-cancer, anti-inflammatory, antioxidant, neuroprotective, antimicrobial, anti-fibrotic, and potential anti-Alzheimer’s effects in vitro and in vivo[1][3][4][5][7][9]. Its health impacts are being actively researched as a nutraceutical and for possible use as a supportive agent in cancer therapy and chronic inflammatory diseases[1][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oleocanthal.